Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company
Cue Biopharma(US:CUE) Globenewswire·2026-05-01 04:05Proven immunology-focused executive and physician-scientist who has led companies from inception to IPO, driven multiple regulatory approvals, and helped build multi-billion-dollar therapeutic portfoliosBOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced the ...